Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MACARONI-23 pediatric Crohn's disease trial of guselkumab
jRCT2031230352Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in Crohn's disease (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of participants with clinical remission at Week 52 and Percentage of participants who achieve endoscopic response at Week 52. Started Jul 2024; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031230352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230352.